# A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

> **NCT07693777** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Zhejiang Doer Biologics Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Severe Hypertriglyceridemia (sHTG)
- Hypertriglyceridemia

## Interventions

- **BIOLOGICAL:** DR10624 Injection
- **OTHER:** Matching Placebo for DR10624

## Key facts

- **NCT ID:** NCT07693777
- **Lead sponsor:** Zhejiang Doer Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2029-02-14
- **Final completion:** 2029-12-05
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693777, "A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*